Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV
International Journal of Immunopathology and Pharmacology · 2026-05 · 40
DOI: 10.1177/03946320261451393 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Immunopathology and Pharmacology, online erschienen am 22.05.2026. Verfasst von Thomas Sorrell und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of California, Berkeley, CA, USA. Hauptthemen laut MEDLINE: Ribonuclease P, RNA, Catalytic, Herpesvirus 1, Human, Herpesvirus 8, Human. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: university of california.
Abstract (Originalsprache)
Infections with human herpesviruses are known to be associated with oral lesions and other oral complications. For example, herpes simplex virus 1 (HSV-1) is the causative agent for cold sores. Kaposi’s sarcoma-associated herpesvirus (KSHV) causes oral Kaposi’s sarcoma (KS) and other oral complications among immunocompromised patients, such as HIV-positive individuals. Novel antiviral strategies are needed to effectively treat oral infections caused by HSV-1 and KSHV, given the limitations of current FDA-approved anti-HSV-1 and anti-KSHV therapies. Nucleic acid-based gene-interfering molecules, such as antisense oligonucleotides, ribozymes, and small interfering RNA (siRNA), are promising gene-targeting agents for therapeutic applications. Ribozymes derived from the catalytic RNA subunit of RNase P in Escherichia coli represent a novel class of RNA-based gene targeting molecules for degrading target mRNAs and modulating gene expression. Methods have been developed to engineer RNase P ribozymes that more effectively suppress gene expression. In this review, we summarize the recent advances in using RNase P ribozymes to block the expression of HSV-1 and KSHV genes and inhibit the infection of HSV-1 and KSHV. Moreover, we discuss the potential of engineered RNase P ribozymes as therapeutics to treat infections and associated diseases caused by HSV-1 and KSHV in the oral cavity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, University of California, Berkeley, CA, USA.
- Department of Molecular Cell Biology, University of California, Berkeley, CA, USA.
- Program in Comparative Biochemistry, University of California, Berkeley, CA, USA.
ORCID-Profile: Fenyong Liu
Förderung
- university of california
Zitieren
APA
Sorrell, T., & Liu, F. (2026). Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV. International Journal of Immunopathology and Pharmacology, 40. https://doi.org/10.1177/03946320261451393
Vancouver
Sorrell T, Liu F. Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV. International Journal of Immunopathology and Pharmacology. 2026;40. doi:10.1177/03946320261451393
BibTeX
@article{Sorrell2026,
author = {Sorrell, Thomas and Liu, Fenyong},
title = {Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2026},
volume = {40},
doi = {10.1177/03946320261451393}
}
EUVIMED